On May 13, 2025, Needham analyst Serge Belanger reiterated a "Buy" rating for MoonLake Biopharma (MLTX, Financial). The analyst has maintained the price target at $66.00 USD, aligning with the prior assessment.
This recent analysis confirms Needham's continued confidence in MoonLake's market performance. Both the current and previous ratings from Needham stand at "Buy," with no adjustments to the price target or rating since the previous evaluation.
Investors and stakeholders in MoonLake (MLTX, Financial) are encouraged to consider these maintained metrics, which highlight the consistent outlook of Needham despite fluctuating market conditions. Keeping the price target steady at $66 indicates a stable projection for the company's future valuation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for MoonLake Immunotherapeutics (MLTX, Financial) is $76.50 with a high estimate of $104.00 and a low estimate of $65.00. The average target implies an upside of 90.39% from the current price of $40.18. More detailed estimate data can be found on the MoonLake Immunotherapeutics (MLTX) Forecast page.
Based on the consensus recommendation from 16 brokerage firms, MoonLake Immunotherapeutics's (MLTX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
